Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status (INSTEP)

被引：10

作者：

Goss, Glenwood

Ferry, David

Laurie, Scott

Wierzbicki, Rafal

Thompson, Joyce

Biesma, B.

Duffield, Emma

Ghiorghiu, Serban

Zarenda, Marc

Armour, Alison

机构：

[1] Ottawa Hosp Reg Canc Ctr, Ottawa, ON, Canada

[2] New Cross Hosp, Wolverhampton, England

[3] Durham Reg Canc Ctr, Oshawa, ON, Canada

[4] Birmingham Heartlands Hosp, Birmingham, W Midlands, England

[5] Jeroen Bosch Ziekenhuis, sHertogenbosch, Netherlands

[6] Astrazeneca, Macclesfield, Cheshire, England

[7] Astrazeneca, Mississauga, ON, Canada

来源：

关键词：

D O I：

10.1097/01.JTO.0000283154.03863.ae

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S340 / S340

页数：1